Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | PDE4A | P27815 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | TNF | P01375 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558655 | 0.97 | POLB (0.72) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7564102 | 0.90 | PDE4A (0.60) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7564474 | 0.87 | POLB (0.73) | LMNAPOLBHIF1ASMN1; SMN2RXFP1 | |
| SCHEMBL7802032 | 0.86 | PDE4A (0.88) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7567218 | 0.86 | ALDH1A1 (0.58) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL2793931 | 0.86 | POLB (0.75) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL3116289 | 0.85 | POLB (0.86) | LMNAPOLBHIF1ASMN1; SMN2RXFP1 | |
| SCHEMBL10784646 | 0.84 | PDE4A (0.84) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL9297147 | 0.84 | PDE4A (0.80) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL6346960 | 0.84 | POLB (0.69) | LMNACYP1A2NFKB1ACHEPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT | 2002-01-24 | — | — | US | disclosed |
| EP-0758239-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995026727-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-12 | — | — | WO | disclosed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | EPX, XDH, MPO | LMNA 2835/4885CYP1A2 334/4885NFKB1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.